牙科网络元分析的方法质量:一个元研究
Anelise Fernandes Montagner1, Patricia Daniela Melchiors Angst2, Daniela Prócida Raggio3
1Universidade Federal de Pelotas - UFPel, Graduate Program in Dentistry, Pelotas, RS, Brazil.
Brazilian oral research
|July 12, 2023
概括
这一元研究评估了牙科领域的网络元分析 (NMA),发现方法质量中等,偏见风险高,特别是在研究选择方面. 建议对未来的牙科NMA进行改进的规划和遵守报告准则.
科学领域:
- 牙科研究 牙科研究
- 超级研究的研究.
- 基于证据的牙科.
背景情况:
- 网络元分析 (NMA) 对于合成牙科随机临床试验的证据至关重要.
- 评估NMA的方法质量和偏差风险对于可靠的证据综合至关重要.
研究的目的:
- 提供关于牙科中NMA的方法质量和偏差风险的概述.
- 评估遵守PRISMA-NMA报告准则,并使用AMSTAR-2和ROBIS工具评估质量.
- 调查报告遵守和质量/偏见评估之间的相关性.
主要方法:
- 搜索了数据库,查找随机临床试验的NMA,在牙科中获得临床结果,直到2022年1月.
- 两位审查员独立选了研究,提取了数据,并评估了对PRISMA-NMA的遵守.
- 评估了AMSTAR-2的方法质量和ROBIS的偏差风险.
主要成果:
- 包括62个NMA,表现出不同的方法质量;51.6%是中等质量的 (AMSTAR-2).
- 坚持PRISMA-NMA的情况各不相同;只有58.1%的潜在注册协议. 报告问题包括NMA几何学,一致性评估和偏差风险评估.
- 罗比斯评估表明,在研究资格标准和选择领域存在高偏差风险.
- 在PRISMA-NMA依从性和AMSTAR-2/ROBIS结果之间发现了中等相关性 (rho < 0.6).
结论:
- 牙科的网络元分析通常具有中等的方法质量.
- 存在重大偏见风险,特别是在研究的识别和选择方面.
- 未来的牙科NMA需要更好的规划,执行和遵守既定的报告和质量评估标准.
更多相关视频
09:50Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
Published on: February 12, 2015
11.2K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
605
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
01:12Hazard Ratio
163
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
163